Neuroscience basis of clinical depression: Implications for future antidepressant drug development

Journal of Psychiatric Practice

Volumn 15, Issue 2, 2009, Pages 125-132

  Preskorn, Sheldon H ^a   Drevets, Wayne C ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Amygdala; Antidepressant drug development; Brain imaging; Clinical depression; Genetics; Hippocampus; Neuroscience

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROTRANSMITTER;

AMYGDALOID NUCLEUS; DEPRESSION; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL HEALTH CARE; NEUROSCIENCE; NEUROTRANSMISSION; PATHOGENESIS; PATIENT EDUCATION; PSYCHOEDUCATION; REVIEW;

ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEUROSCIENCES; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 67650360863     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000348365.96300.07     Document Type: Review

References (48)

1. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-81.
2. Salloway S, Cummings J. Subcortical disease and neuropsychiatric illness. J Neuropsychiatry Clin Neurosci 1994;6:93-9.
3. Ongür D, Price JL. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cereb Cortex 2000;10:206-19.
4. Swanson LW. The hypothalamus. In: Bjorklund A, Hokfelt T, eds. Handbook of chemical neuroanatomy, 5: Integrated systems of the CNS, part I. Philadelphia, PA: Elsevier; 1987:1-124.
5. Davidson RJ, Pizzagalli D, Nitschke JB, et al. Depression: Perspectives from affective neuroscience. Annu Rev Psychol 2002;53:545-74.
6. Drevets WC, Thase ME, Moses-Kolko EL, et al. Serotonin-1A receptor imaging in recurrent depression: Replication and literature review. Nucl Med Biol 2007;34:865-77.
7. MacDonald AW 3rd, Cohen JD, Stenger VA, et al. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000;288:1835-8.
8. Davidson RJ. Affective neuroscience and psychophysiology: Toward a synthesis. Psychophysiology 2003;40:655-65.
9. Drevets WC. Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001;11: 240-9.
10. Fanselow MS. Contextual fear, gestalt memories, and the hippocampus. Behav Brain Res 2000;110:73-81.
11. Reul JM, de Kloet ER. Anatomical resolution of two types of corticosterone receptor sites in rat brain with in vitro autoradiography and computerized image analysis. J Steroid Biochem 1986;24:269-72.
12. Squire LR, Knowlton BJ. The medial temporal lobe, the hippocampus, and the memory systems of the brain. In: Gazzaniga MS, ed. The new cognitive neurosciences, 2nd ed. Cambridge, MA: The MIT Press; 2000:765-76.
13. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002;12:527-44.
14. Drevets WC, Gadde KM, Krishnan RR. Neuroimaging studies of depression. In: Charney DS, Nestler EJ, Bunney BS, eds. The neurobiological foundation of mental illness, 2nd edition, New York: Oxford University Press; 2004: 461-90.
15. Kennedy SH, Evans KR, Krüger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001;158:899-905.
16. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
17. Drevets WC, Furey ML. Emotional disorders: Depression and the brain. In: Squire LR, ed. Encyclopedia of neuroscience, fourth edition, volume 3. Oxford: Academic Press; 2009: 459-70.
18. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: The role of stress and medical comorbidity. Biol Psychiatry 2000;48:791-800.
19. Paul IA, Skolnick P. Glutamate and depression: Clinical and preclinical studies. Ann N Y Acad Sci 2003;1003: 250-72.
20. McEwen BS. Physiology and neurobiology of stress and adaptation: Central role of the brain. Physiol Rev 2007; 87:873-904.
21. Preskorn SH. Results of the STAR*D study: Implications for clinicians and drug developers. J Psychiatr Pract 2009;15:45-9.
22. Walker DL, Toufexis DJ, Davis M. Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol 2003;463:199-216.
23. Davis M, Shi C. The extended amygdala: Are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Ann N Y Acad Sci 1999;877:281-91.
24. Hasler G, Fromm S, Alvarez RP, et al. Cerebral blood flow in immediate and sustained anxiety. J Neurosci 2007;27: 6313-9.
25. Phillips ML, Drevets, WC, Rauch, SL, et al. The neurobiology of emotion perception I: Towards an understanding of the neural basis of normal emotion perception. Biol Psychiatry 2003;54:504-14.
26. Diorio D, Viau V, Meaney MJ. The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. J Neurosci 1993;13:3839-47.
27. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-4.
28. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63: 856-64.
29. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008;28:631-7.
30. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55: 580-92.
31. Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: Relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians 1999;111: 22-34.
32. Habib KE, Gold PW, Chrousos GP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am 2001;30:695-728; vii-viii.
33. Cannon DM, Carson RE, Nugent AC, et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006;63:741-7.
34. Preskorn SH. What to do if the patient does not respond well to initial antidepressant therapy. In: Preskorn SH. Outpatient management of depression. Caddo, OK: Professional Communications; 2009: 223-55.
35. Lopez JF, Chalmers DT, Little KY, et al. Regulation of serotonin 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry 1998;43: 547-73.
36. Meijer OC, Van Oosten RV, De Kloet ER. Elevated basal trough levels of corticosterone suppress hippocampal 5-hydroxytryptamine(1A) receptor expression in adrenally intact rats: Implication for the pathogenesis of depression. Neuroscience 1997;80:419-26.
37. Drevets WC, Thase M, Moses-Kolko E, et al. Serotonin-1A receptor imaging in recurrent depression: Replication and literature review. Nucl Med Biol 2007;34:865-77.
38. Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002;297:400-3.
39. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-11.
40. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23:587-90.
41. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-9.
42. Preskorn SH. The rational basis for the development and use of newer antidepressants. In: Preskorn SH. Outpatient management of depression. Caddo, OK: Professional Communications; 2009:77-121.
43. Gould E. Serotonin and hippocampal neurogenesis. Neuropsychopharmacology 1999;21(2 suppl):46S-51S.
44. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54: 597-606.
45. Kojima M, Klein RL, Hatanaka H. Pre- and post-synaptic modification by neurotrophins. Neurosci Res 2002;43: 193-9.
46. Eriksson PS, Wallin L. Functional consequences of stress related suppression of adult hippocampal neurogenesis - a novel hypothesis on the neurobiology of burnout. Acta Neurol Scand 2004;110:275-80.
47. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70-5.
48. Modern drug development and the human genome project. Series of columns published between 2000 and 2002 in the Journal of Psychiatric Practice. Available at www.preskorn.com/column4.html.